



Case Studies

From our portfolio of services



Case Studies

Dig Worldwide is a specialist agency, providing back to basics primary competitive intelligence in a legal and ethical manner. We are based near London but work globally.

Everything that Dig Worldwide does is based on asking the right questions of both our clients and our sources. This ensures effort is focused on what matters rather than peripheral activity; providing you with robust and validated intelligence insights.

What is back to basics? When gathering primary intelligence, we utilise our Source Enrichment Process along with traditional methods; spending our time engaging with high numbers of relevant and informed sources rather than scanning the secondary domain, data mining or interviewing only a handful of people.

If you need to know your competitors next moves, we are here to help.

Case Study 01 – Biosimilars Tracker / Congress

Who?	Top 50 Pharmaceutical
What?	Long Term Tracker
Why?	The relatively stable Somastatin Analogue market is migrating into a more dynamic space, with new biosimilar entrants shaking up the market for all players concerned. In order for our client to stay competitive, they needed to understand which companies were developing biosimilars, hybrids or generics versions of their product, the likelihood of launch, time lines, regulatory routes, clinical profile, trial details and partnering potential
Where?	EU, Korea, China, India and USA
When?	Q2 2012 – Q4 2013
How?	Dig Worldwide contacted target companies, conducted face-to-face meetings (Korea) and attended the CPhI congress to answer Key Competitive Questions. Dig contacted over 85 internal sources across the globe as well as external sources relevant to the area. This translated into an excess of 35 substantive interviews
Result	Once the intelligence was collected, the companies were broken down in high, medium and low threat and monitored accordingly. Dig provides the client with quarterly updates on competitor milestones



Case Studies

Case Study 02 – Delivery Devices Tracker



Who?	Top 50 Pharmaceutical
What?	Long Term Tracker
Why?	Our client was concerned about these potential entrants utilising various forms of transdermal delivery to differentiate their products which would threaten our client's own patch franchise
Where?	EU, India, APAC and USA
When?	Q1 2013
How?	Dig focused its primary interviews across a wide range of sources from regulators, API suppliers, wholesalers, regulatory agencies, industry associations, specialists, nurses, target company, marketing service suppliers and patient associations. Key Questions included timelines to launch, regulatory approaches, how they overcame manufacturing hurdles, where they would launch and differences to what was already on the market
Result	Dig was able to uncover which competitors would progress through to launch and those that were destined to fail. For those that were able to market the product, Dig provided launch timelines in 10 countries down to the month, SWOT analysis, regulatory approaches and marketing strategies which are updated on a quarterly basis



Case Study 03 – Manufacturing Tracker




Who?	Top 50 Pharmaceutical
What?	Determination of the manufacturing methodology, capacity and future expansion plans of two new entrants into the Severe Pain market place
Why?	Having an accurate assessment of the manufacturing capability and capacity of two difficult to manufacture products would allow our client to accurately assess volume and pricing assumptions, their impact on future sales forecasts as well as the likely launch date based on manufacturing readiness
Where?	USA and Japan
When?	Q1 2012 – Q4 2013
How?	Key sources working for the target companies as well as equipment/consumable suppliers, environmental agencies and engineering consultancies were all contacted over an 20 month period. These were initially found using Dig's proprietary Source Enrichment capability
Result	Detailed current and future facility plans were obtained, equipment models and performance specifications were gathered, engineering qualification was tracked from installation to GMP performance qualification. Future expansion plans and associated timelines were determined. Samples of raw material were also obtained from a specialist supplier in Japan which allowed our client to benchmark their own product attributes against a future competitor prior to launch



Case Studies

Case Study 04 – Cardiovascular Landscape / Congress



Who?	Top 50 Pharmaceutical
What?	Ad-hoc retainer tracking three competitors in the anticoagulation space
Why?	Our clients' principle competitors in the rapidly evolving anticoagulation market place were creating waves in terms of clinically superior data and marketing initiatives which required constant tracking in order to counter accordingly
Where?	Europe and the USA
When?	Q2 2012 – Q3 2013
How?	Dig approached sources within the competitor companies on both sides of the Atlantic, assisted by Dig's bespoke Source Enrichment tool. Dig interviewed clinical, regulatory as well as senior marketing and sales employees of both companies augmented by advisory board members and principal investigators
Result	The regulatory and pre-marketing progress of the targets were successfully monitored on an ad-hoc basis. This resulted in real-time awareness and insights into competitor activity across the majority of the EU countries and the USA



Case Study 05 – Oncology Landscape / Congress



Who?	Top 50 Pharmaceutical
What?	Dig Worldwide has worked across a number of areas including: Liver, Neuroendocrine, Male (Prostate), Female (Breast/Ovarian) and Bladder cancers
Why?	The projects consisted of understanding competitor launch timelines, clinical trial details, entry strategies (including South East Asia), pricing points, key messaging and determining threat levels
Where?	Global
When?	Various projects have been ongoing since Q4 2011
How?	In all cases, Dig Worldwide attended a number of congresses, engaged with relevant sources such as KOLs, principal investigators and the target companies. Efforts were focused on the competitors activities in the various Oncologic sectors which provided the clients with competitor insights
Result	Dig Worldwide successfully contributed to brand plans, evolving competitor landscapes and provided the clients with an up-to-date understanding of the clinical and strategic particulars of the competitor sets



Case Studies

Case Study 05 – Intelligence Gathering In China

Snapshot

- Who?** Top 50 Pharmaceutical
- What?** Our client wanted to know the size and structure of four competitors' China based field forces prior to launching its own product for two major CV indications
- Why?** Share-of-voice is a key factor for success in China. Our client needed to ensure that the size of its own field force could compete against its principal competitors
- Where?** Peoples Republic of China
- When?** Q1 2013 – Q2 2013
- How?** Our network approached ~ 100 sources across 16 provinces in China, encompassing all of the major urban centres. We interviewed primarily District and Regional Sales Managers. Because of the variability of intelligence gathered in China, we also crossed checked the data with knowledgeable sources located at the target companies Chinese HQs as well as the EU/US HQ
- Result** We successfully mapped the field forces across all target organisations as well as gathered intelligence on the number of representatives promoting other non-CV therapy areas. Dig established details of the management structure, number of Medical Scientific Liaison employees as well as future hiring plans (which were linked to the promotion of new indications)



Case Study 06 – Raw Material (API) Identification

Snapshot

- Who?** Top 50 Pharmaceutical
- What?** Active Pharmaceutical Identification
- Why?** Dig was engaged to uncover the identify and location of an API provider or providers who were supplying our clients competitors. The source of API was a complete unknown and once identified, this would allow for tracking of the API supply
- Where?** EU, The Americas, South East Asia, India and China
- When?** Q2 2012
- How?** Dig generated a short list of potential suppliers which were located across the globe. We then preformed an initial intelligence gathering sweep of over 20 suppliers to determine if they did or did not supply the competitor. Finally, Dig defined a list of four potentials to perform a more in-depth analysis and elicit intelligence from
- Result** Dig uncovered the identify of the primary supplier as well as two secondary API suppliers for two future competitors. In addition, we uncovered and subsequently tracked the planned volumes of API that were intended to be shipped over a period of 12 months. This allowed our client to use import statistics to cross check the volumes of API being shipped from APAC and make an assessment of how much competing product would sell



Case Studies

Case Study 07 – COGs Benchmarking Landscape



Who?	Top 50 Pharmaceutical
What?	Benchmarking our clients COGs across two therapeutic areas against peers as well as direct competitors
Why?	New management came into play and wanted to understand if further efficiencies could be achieved with regards to cost of goods
Where?	UK, Belgium, France and the USA
When?	Q1 2013 – Q2 2013
How?	Internal sources (or recent past employees) specific to the target companies were contacted. These were found using Dig's proprietary Source Enrichment capability. COG numbers were derived as a "top-down" ratio of the average selling price of a standardised unit. Using ratios usually reflects operational reality verses bottom-up and is also a legal and ethical means of deriving the numbers
Result	In one therapeutic area, our client was the most efficient producer and in another, it came as substantive shock that it cost significantly more to produce an equivalent unit than its peer. Actions to correct this anomaly are being discussed



Case Study 08 – Toxins Snapshot



Who?	Top 50 Pharmaceutical
What?	An in-depth investigation into the life-cycle-management initiatives of nine companies for cosmetic and therapeutic indications of botulinum toxin
Why?	To provide clear insight into the competitors movements within their toxin franchise and understand if they are developing new formulations/delivery devices
Where?	EU, US, China, Korea, Australia
When?	Q3 2013 – Q4 2013
How?	Internal sources (or recent past employees) specific to the target companies were identified alongside peripheral sources which included clinical experts and opinion leaders as well as logistic, equipment and IT suppliers. These were found using Dig's proprietary Source Enrichment capability and were interviewed either in person (as in Korea) or via the telephone. During the course of the assignment, 157 sources were engaged which translated into 42 substantive interviews
Result	A comparative threat matrix to our client was developed which included anticipated next generation product profiles, planned regulatory filing and regional launch objectives. Technology transfer initiatives, research collaboration agreements, clinical difficulties as well as financial health issues were identified and described during the course of the assignment. The results of this project were presented to the brand team and were used to adjust future sales forecasts and refine marketing plans



Case Studies

ABOUT DIG WORLDWIDE

Dig Worldwide is a specialist agency founded in 2011 providing back to basics primary competitive intelligence. We spend the majority of our time talking to high numbers of informed sources rather than passively searching the Internet and recycling information or interviewing only a handful of sources. Everything that Dig Worldwide does is based on asking the right questions of both our clients and potential sources of intelligence. This ensures that our efforts are focused on what matters from an intelligence gathering perspective rather than peripheral activity.

Reliability is at the core of who we are, providing a flexible yet consistent service. We always act ethically when gathering intelligence and deliver results in a thought provoking and analysed manner.

For more information, please contact us at info@dig-worldwide.com or call Beth Elliott or Tony Nagle from Dig Worldwide on +44 (0) 1304 806 988